Login / Signup

Current state and prospects of biotechnology in Central and Eastern European countries. Part I: Visegrad countries (CZ, H, PL, SK).

Markus DettenhoferMiroslav OndrejovičViktória VásáryPawel KaszyckiTomasz TwardowskiStanislav StuchlíkJán TurňaMunis DundarKevan M A GartlandStanislav Miertuš
Published in: Critical reviews in biotechnology (2018)
Innovation is a key determinant of sustainable growth. Biotechnology (BT) is one such industry that has witnessed a revolution in innovative ideas leading to the founding of many new companies based on providing products, solutions and services, stretching from the food industry to environmental remediation, and new medicines. BT holds much promise for the development of national and local economies, however, this requires a strategic approach involving actors within government, industry, and academia working in concert to maximize this potential. This first article reviews the current "state of play" in the field of BT within the Central Eastern European (CEE) countries. For the purposes of this article, CEE refers to the countries of Czech Republic, Hungary, Poland, and Slovakia (the so-called Visegrad - V4 countries). We examine the components that support the creation and development of a BT sector in CEE and also highlight the barriers to these objectives. Clearly setting priorities for the countries' policy agenda, as well as the alignment of Smart Specialization Strategy will help to focus efforts. Recent investments in R&D infrastructure within CEE have been substantial, but conditions will need to be optimized to harness these largely European investments for effective use towards SME high-tech development.
Keyphrases
  • healthcare
  • south africa
  • mental health
  • public health
  • quality improvement
  • human health
  • randomized controlled trial
  • machine learning
  • deep learning
  • current status